Why Reckitt Benckiser Group Plc Is One Of My Favourite Stocks

Even though there are hundreds of UK-listed stocks to choose from, Reckitt Benckiser Group Plc (LON: RB) remains one of my favourites.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

As every Fool knows, it is crucial to keep emotions out of investment decisions. The two simply do not mix and, as I have found to my cost in the past, investing in a company you like or whose good/service you gain enjoyment from is not a sound investment strategy.

Indeed, when I talk about Reckitt Benckiser (LSE: RB) (NASDAQOTH: RBGPY.US) being one of my favourite stocks, I am speaking with regard to its attributes as a company and an investment, as well as the potential it has to grow over the long-term.

Of course, the company has excellent prospects over the shorter term, too. CEO Rakesh Kapoor recently announced that he expected around half of the company’s revenue to be derived from China by 2015. This is a year earlier than planned and shows that, as the Chinese population becomes more affluent, they are demanding more consumer staples and medicines. Both of which are core areas for Reckitt Benckiser.

Certainly, many of us in the UK would view some of the company’s products as being basic and not particularly glamorous or exciting. For instance, Gaviscon, Calgon, Finish and Nurofen are not exactly products that set the pulse racing.

However, they improve the quality of people’s lives, whether through convenience or improved health. Furthermore, established brands in the developed world are proving popular in emerging markets due to their quality and reliability.

Therefore, there is the potential for Reckitt Benckiser to substantially increase sales in a wide range of developing nations, as people become more affluent and seek basic, reliable and high-quality medicines and consumer staples. The key difference between Reckitt Benckiser and many of its competitors in the consumer goods sector is that its goods are considered near-necessities and, as such, have wider accessibility and lower price points.

Shares currently trade on a price-to-earnings ratio of 19.7, which is a premium to both the consumer goods industry group (17.5) and the FTSE 100 (12.9). However, with near-limitless potential, I believe the premium is actually quite reasonable and Reckitt Benckiser is a company I will be looking to buy and hold for a long time.

Of course, you may be looking for other ideas in the FTSE 100 and, if you are, I would recommend this exclusive wealth report which reviews five particularly attractive possibilities.

All five blue chips offer a mix of robust prospects, illustrious histories and dependable dividends, and have just been declared by The Motley Fool as “5 Shares You Can Retire On“.

Simply click here for the report — it’s completely free!

> Peter does not own shares in Reckitt Benckiser.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

Young Black man sat in front of laptop while wearing headphones
Investing Articles

Which of these is the best dirt cheap FTSE 100 stock to buy for 2024?

I'm building a list of the greatest FTSE 100 stocks to buy for the long term. But are these UK…

Read more »

Investing Articles

What’s on the cards for the BT share price in 2024?

After a turbulent few years, could the BT share price experience a better year ahead and how? This Fool investigates.

Read more »

Businesswoman analyses profitability of working company with digital virtual screen
Investing Articles

Lloyds shares could reach £1.50 in 2024

Lloyds shares rising from 43p to £1.50 in 2024 sounds like a tall order, but here is how the unloved…

Read more »

Long-term vs short-term investing concept on a staircase
Investing Articles

Should investors rush to buy Aviva shares before the end of the year?

The 7.5% dividend yield on Aviva shares is attractive. But Stephen Wright thinks a different FTSE 100 insurer is a…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

2 UK stocks for value investors to consider buying before the end of the year

Exploiting cyclical downturns can be a great way for value investors to find stocks to buy at bargain prices. Stephen…

Read more »

Young woman holding up three fingers
Investing Articles

I’d earn £1,260 in passive income by investing a £20k Isa in these 3 ultra-high-yield stocks

I'm on the hunt for passive income and I reckon the following FTSE 100 stocks should help me generate it…

Read more »

Asian man looking concerned while studying paperwork at his desk in an office
Investing Articles

Could these beleaguered FTSE 100 stocks stage a turnaround?

Could these FTSE 100 stocks be primed for recovery after difficult times? Sumayya Mansoor takes a look at what could…

Read more »

Young black man looking at phone while on the London Overground
Investing Articles

Is this FTSE 100 giant one of the best income stocks out there?

Our writer takes a closer look at this medical business as a potential income stock for her portfolio, even though…

Read more »